Cryoport (CYRX) Projected to Post Earnings on Wednesday

Cryoport (NASDAQ:CYRX - Get Free Report) is expected to be issuing its Q1 2025 quarterly earnings data after the market closes on Wednesday, May 7th. Analysts expect the company to announce earnings of ($0.28) per share and revenue of $56.19 million for the quarter. Cryoport has set its FY 2025 guidance at EPS.

Cryoport (NASDAQ:CYRX - Get Free Report) last posted its earnings results on Tuesday, March 4th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.33) by ($0.09). The company had revenue of $59.53 million for the quarter, compared to analyst estimates of $58.71 million. Cryoport had a negative return on equity of 13.35% and a negative net margin of 70.08%. During the same quarter in the prior year, the business posted ($0.29) EPS. On average, analysts expect Cryoport to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Cryoport Stock Performance

CYRX stock traded up $0.40 during mid-day trading on Friday, hitting $5.86. 345,885 shares of the company were exchanged, compared to its average volume of 545,954. Cryoport has a 1-year low of $4.58 and a 1-year high of $17.41. The business has a 50 day simple moving average of $5.80 and a 200-day simple moving average of $6.90. The company has a current ratio of 5.70, a quick ratio of 5.32 and a debt-to-equity ratio of 0.48. The stock has a market capitalization of $293.80 million, a PE ratio of -1.73 and a beta of 1.92.

Wall Street Analyst Weigh In

A number of research analysts have commented on the company. Needham & Company LLC reaffirmed a "buy" rating and issued a $11.00 price objective on shares of Cryoport in a report on Wednesday, April 16th. UBS Group raised their price target on shares of Cryoport from $10.00 to $11.00 and gave the stock a "buy" rating in a research report on Tuesday, April 1st. Roth Mkm restated a "buy" rating and set a $15.00 target price on shares of Cryoport in a research report on Tuesday, April 1st. Finally, Guggenheim reiterated a "buy" rating and issued a $10.00 price target on shares of Cryoport in a research report on Wednesday, April 16th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $11.67.

Insider Buying and Selling

In other news, CEO Jerrell Shelton sold 4,620 shares of Cryoport stock in a transaction on Monday, March 17th. The stock was sold at an average price of $6.29, for a total value of $29,059.80. Following the transaction, the chief executive officer now owns 765,399 shares in the company, valued at approximately $4,814,359.71. This trade represents a 0.60 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In the last 90 days, insiders have sold 19,830 shares of company stock worth $118,353. Corporate insiders own 10.10% of the company's stock.

Cryoport Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.